Biologics in the Treatment of Eosinophilic Esophagitis: Ready for Use?
Clinical Gastroenterology and Hepatology · 2023
DOI: 10.1016/j.cgh.2023.07.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023. Verfasst von Diana L Snyder und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: Snyder.diana@mayo.edu. Hauptthemen laut MEDLINE: Enteritis, Gastritis, Biological Products, Esophagitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: Snyder.diana@mayo.edu.
- Center for Esophageal Diseases and Swallowing and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolin…
Zitieren
APA
Snyder, D. L., & Dellon, E. S. (2023). Biologics in the Treatment of Eosinophilic Esophagitis: Ready for Use?. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.07.025
Vancouver
Snyder DL, Dellon ES. Biologics in the Treatment of Eosinophilic Esophagitis: Ready for Use?. Clinical Gastroenterology and Hepatology. 2023. doi:10.1016/j.cgh.2023.07.025
BibTeX
@article{Snyder2023,
author = {Snyder, Diana L and Dellon, Evan S},
title = {Biologics in the Treatment of Eosinophilic Esophagitis: Ready for Use?},
journal = {Clinical Gastroenterology and Hepatology},
year = {2023},
doi = {10.1016/j.cgh.2023.07.025}
}
EUVIMED